1. Home
  2. CGEM vs PSNL Comparison

CGEM vs PSNL Comparison

Compare CGEM & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$14.87

Market Cap

780.4M

Sector

Health Care

ML Signal

N/A

Logo Personalis Inc.

PSNL

Personalis Inc.

N/A

Current Price

$8.18

Market Cap

729.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CGEM
PSNL
Founded
2016
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
780.4M
729.1M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
CGEM
PSNL
Price
$14.87
$8.18
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$29.89
$11.50
AVG Volume (30 Days)
780.3K
1.3M
Earning Date
05-29-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.58
EPS
N/A
N/A
Revenue
N/A
$69,648,000.00
Revenue This Year
N/A
$16.94
Revenue Next Year
N/A
$36.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.68
$2.83
52 Week High
$16.74
$11.50

Technical Indicators

Market Signals
Indicator
CGEM
PSNL
Relative Strength Index (RSI) 57.60 46.17
Support Level $6.65 $7.37
Resistance Level $16.74 $9.64
Average True Range (ATR) 1.09 0.68
MACD -0.00 -0.04
Stochastic Oscillator 58.17 39.30

Price Performance

Historical Comparison
CGEM
PSNL

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Share on Social Networks: